<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1271" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1271/" /><meta name="ncbi_pagename" content="Hepatic Veno-Occlusive Disease with Immunodeficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hepatic Veno-Occlusive Disease with Immunodeficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hepatic Veno-Occlusive Disease with Immunodeficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/01/12" /><meta name="citation_author" content="Tony Roscioli" /><meta name="citation_author" content="John B Ziegler" /><meta name="citation_author" content="Michael Buckley" /><meta name="citation_author" content="Melanie Wong" /><meta name="citation_pmid" content="20301448" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1271/" /><meta name="citation_keywords" content="VODI" /><meta name="citation_keywords" content="Sp110 nuclear body protein" /><meta name="citation_keywords" content="SP110" /><meta name="citation_keywords" content="Hepatic Veno-Occlusive Disease with Immunodeficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hepatic Veno-Occlusive Disease with Immunodeficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Tony Roscioli" /><meta name="DC.Contributor" content="John B Ziegler" /><meta name="DC.Contributor" content="Michael Buckley" /><meta name="DC.Contributor" content="Melanie Wong" /><meta name="DC.Date" content="2017/01/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1271/" /><meta name="description" content="Hepatic veno-occlusive disease with immunodeficiency (VODI) is characterized by: (1) primary immunodeficiency; and (2) terminal hepatic lobular vascular occlusion and hepatic fibrosis manifest as hepatomegaly and/or hepatic failure. Onset is usually before age six months. The immunodeficiency comprises severe hypogammaglobulinemia, clinical evidence of T-cell immunodeficiency with normal numbers of circulating T cells, absent lymph node germinal centers, and absent tissue plasma cells. Bacterial and opportunistic infections including Pneumocystis jirovecii infection, mucocutaneous candidiasis, and enteroviral or cytomegalovirus infections occur. In the past the prognosis for affected individuals was poor, with 100% mortality in the first year of life if unrecognized and untreated with intravenous immunoglobulin (IVIG) and Pneumocystis jirovecii prophylaxis. However, with early recognition and treatment there is a marked improvement in prognosis." /><meta name="og:title" content="Hepatic Veno-Occlusive Disease with Immunodeficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Hepatic veno-occlusive disease with immunodeficiency (VODI) is characterized by: (1) primary immunodeficiency; and (2) terminal hepatic lobular vascular occlusion and hepatic fibrosis manifest as hepatomegaly and/or hepatic failure. Onset is usually before age six months. The immunodeficiency comprises severe hypogammaglobulinemia, clinical evidence of T-cell immunodeficiency with normal numbers of circulating T cells, absent lymph node germinal centers, and absent tissue plasma cells. Bacterial and opportunistic infections including Pneumocystis jirovecii infection, mucocutaneous candidiasis, and enteroviral or cytomegalovirus infections occur. In the past the prognosis for affected individuals was poor, with 100% mortality in the first year of life if unrecognized and untreated with intravenous immunoglobulin (IVIG) and Pneumocystis jirovecii prophylaxis. However, with early recognition and treatment there is a marked improvement in prognosis." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1271/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/vodi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1271/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B994AE041150100000000026E0101.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1271_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1271_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hemo-b/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hep/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1271_"><span class="title" itemprop="name">Hepatic Veno-Occlusive Disease with Immunodeficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: VODI</div><p class="contrib-group"><span itemprop="author">Tony Roscioli</span>, MBBS, FRACP, PhD, <span itemprop="author">John B Ziegler</span>, MBBS, FRACP, MD, <span itemprop="author">Michael Buckley</span>, MBChB, PhD, FRCPA, FHGSA, and <span itemprop="author">Melanie Wong</span>, MBBS, FRACP, FRCPA, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1271_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1271_ai__"><div class="contrib half_rhythm"><span itemprop="author">Tony Roscioli</span>, MBBS, FRACP, PhD<div class="affiliation small">Clinical Geneticist, School of Women&#x02019;s and Children&#x02019;s Health<br />University of New South Wales<br />Sydney Children&#x02019;s Hospital<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.gro.navrag@iloicsor.t" class="oemail">ua.gro.navrag@iloicsor.t</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John B Ziegler</span>, MBBS, FRACP, MD<div class="affiliation small">Clinical Immunologist, Sydney Children's Hospital<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.ude.wsnu@relgeiz.j" class="oemail">ua.ude.wsnu@relgeiz.j</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael Buckley</span>, MBChB, PhD, FRCPA, FHGSA<div class="affiliation small">Director, SEALS Molecular and Cytogenetics Laboratory<br />Prince of Wales Hospital<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.vog.wsn.htlaeh@yelkcub.leahcim" class="oemail">ua.vog.wsn.htlaeh@yelkcub.leahcim</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Melanie Wong</span>, MBBS, FRACP, FRCPA, PhD<div class="affiliation small">Clinical Immunologist and Immunopathologist, Children's Hospital Westmead<br />Sydney, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.vog.wsn.htlaeh@gnow.einalem" class="oemail">ua.vog.wsn.htlaeh@gnow.einalem</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 21, 2007</span>; Last Update: <span itemprop="dateModified">January 12, 2017</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="vodi.Summary" itemprop="description"><h2 id="_vodi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hepatic veno-occlusive disease with immunodeficiency (VODI) is characterized by: (1) primary immunodeficiency; and (2) terminal hepatic lobular vascular occlusion and hepatic fibrosis manifest as hepatomegaly and/or hepatic failure. Onset is usually before age six months. The immunodeficiency comprises severe hypogammaglobulinemia, clinical evidence of T-cell immunodeficiency with normal numbers of circulating T cells, absent lymph node germinal centers, and absent tissue plasma cells. Bacterial and opportunistic infections including <i>Pneumocystis jirovecii</i> infection, mucocutaneous candidiasis, and enteroviral or cytomegalovirus infections occur. In the past the prognosis for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals was poor, with 100% mortality in the first year of life if unrecognized and untreated with intravenous immunoglobulin (IVIG) and <i>Pneumocystis jirovecii</i> prophylaxis. However, with early recognition and treatment there is a marked improvement in prognosis.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of VODI is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following clinical diagnostic criteria:</p><ul><li class="half_rhythm"><div>Clinical evidence of primary immunodeficiency</div></li><li class="half_rhythm"><div>Hepatomegaly or evidence of hepatic failure in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> or a <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a></div></li><li class="half_rhythm"><div>Onset usually before age six months</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p>Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SP110</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> establishes the diagnosis if clinical features are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> IVIG and <i>Pneumocystis jirovecii</i> prophylaxis as soon as the diagnosis of VODI is established; appropriate, prompt treatment of infections; consider hepatic transplantation, although rate of complications may be high; bone marrow transplantation may be efficacious with appropriate conditioning therapy.</p><p><i>Prevention of primary manifestations:</i> IVIG and <i>Pneumocystis jirovecii</i> prophylaxis.</p><p><i>Surveillance:</i> Regular monitoring of hepatic function, platelet count, and hemoglobin level; routine monitoring of serum and urine electrolytes as the syndrome of inappropriate anti-diuretic hormone (SIADH) may occur; measurement of immunoglobulin concentrations prior to IVIG infusions; broncho-alveolar lavage to diagnose <i>Pneumocystis jirovecii</i> infection; viral cultures or lung function studies as needed; cerebrospinal imaging to diagnose leukodystrophy when clinically indicated.</p><p><i>Agents/circumstances to avoid:</i> Agents known to predispose to hepatic veno-occlusive disease (hVOD) including cyclophosphamide and senecio alkaloids/bush teas.</p><p><i>Evaluation of relatives at risk:</i> If both pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who are younger than age 12 months to allow for early diagnosis and treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>VODI is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (carriers) and therefore carry one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Heterozygotes are asymptomatic. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both pathogenic variants in a family are known.</p></div></div><div id="vodi.Diagnosis"><h2 id="_vodi_Diagnosis_">Diagnosis</h2><div id="vodi.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hepatic veno-occlusive disease with immunodeficiency (VODI) <b>should be suspected</b> in individuals with the following.</p><p><b>Clinical diagnostic criteria</b></p><ul><li class="half_rhythm"><div>Clinical evidence of immunodeficiency with bacterial and opportunistic infections including <i>Pneumocystis jirovecii</i> infection, mucocutaneous candidiasis, and enteroviral or cytomegalovirus infections</div></li><li class="half_rhythm"><div>Hepatomegaly or evidence of hepatic failure, not explained by other factors, in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a first degree relative (hepatic veno-occlusive disease is usually present and pathognomonic but may not be found, or may have resolved)</div></li><li class="half_rhythm"><div>Onset usually before age six months</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div></li></ul><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div class="half_rhythm">Low serum concentrations of IgA, IgM, and IgG</div><div class="half_rhythm">Note: Immunoglobulin levels are age specific and laboratory specific and thus should be compared against appropriate local reference ranges.</div></li><li class="half_rhythm"><div class="half_rhythm">Normal lymphocyte numbers and CD4 and CD8 percentages</div></li><li class="half_rhythm"><div class="half_rhythm">Normal lymphocyte proliferative responses to mitogens</div></li><li class="half_rhythm"><div class="half_rhythm">Low intracellular cytokine production</div></li></ul><p><b>Radiographic features</b></p><ul><li class="half_rhythm"><div>Hepatic ultrasonography. Features consistent with hepatic veno-occlusive disease (hVOD) may include hepatosplenomegaly, gallbladder wall thickening, increased portal vein diameter, reduced hepatic vein diameter, ascites, and re-canalization of the <i>ligamentum teres</i>.</div></li><li class="half_rhythm"><div>Doppler ultrasound examination. Features consistent with hVOD may include reduced portal venous flow, flow in the para-umbilical vein, and increased resistance in the hepatic artery.</div></li></ul><p><b>Histopathologic features</b></p><ul><li class="half_rhythm"><div>hVOD (also known as sinusoidal obstruction syndrome) may include fibrous concentric narrowing of zone 3 terminal hepatic venules, centrilobular hepatocyte necrosis, and sinusoidal congestion (see <a class="figpopup" href="/books/NBK1271/figure/vodi.F1/?report=objectonly" target="object" rid-figpopup="figvodiF1" rid-ob="figobvodiF1">Figure 1</a>).</div></li><li class="half_rhythm"><div>Note: If hepatic biopsy is contraindicated, hepatic ultrasonography and Doppler ultrasonography may provide supportive evidence of hVOD.</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figvodiF1" co-legend-rid="figlgndvodiF1"><a href="/books/NBK1271/figure/vodi.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figvodiF1" rid-ob="figobvodiF1"><img class="small-thumb" src="/books/NBK1271/bin/vodi-Image001.gif" src-large="/books/NBK1271/bin/vodi-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndvodiF1"><h4 id="vodi.F1"><a href="/books/NBK1271/figure/vodi.F1/?report=objectonly" target="object" rid-ob="figobvodiF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Hepatic biopsy showing vascular obliteration, perivenular fibrosis, zone 3 fibrosis and hepatocyte dropout from a girl who presented at age five months with hepatomegaly and ascites (Picro-Mallory stain 100x) </p></div></div></div><div id="vodi.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of VODI <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical diagnostic criteria. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SP110</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> establishes the diagnosis if clinical features are inconclusive (see <a class="figpopup" href="/books/NBK1271/table/vodi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figvodiTmoleculargenetictestingusedin" rid-ob="figobvodiTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>SP110</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div><div class="half_rhythm">Targeted analysis for the <a class="figpopup" href="/books/NBK1271/table/vodi.T.sp110_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figvodiTsp110pathogenicvariantsdiscuss" rid-ob="figobvodiTsp110pathogenicvariantsdiscuss">c.642delC</a> pathogenic variants can be performed first in individuals of Lebanese ancestry.</div><div class="half_rhythm">Sequence analysis of <i>SP110</i> may be performed in a tiered approach beginning with exons 2, 4, 5 and 8 (reference sequence: LRG_109). Sequencing of the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> of 19 exons and an alternatively spliced <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15 in the Sp110c isoform is performed if neither or only one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in exons 2, 4, 5 and 8.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SP110</i> and other genes of interest (see <a href="#vodi.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered if single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing (and/or use of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that includes <i>SP110</i>) fails to confirm a diagnosis in an individual with features of VODI. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For an introduction to comprehensive genomic testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="vodi.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hepatic Veno-Occlusive Disease with Immunodeficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SP110</i></td><td headers="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13/13 (100%)&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_vodi.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="vodi.TF.1.1"><p class="no_margin">See <a href="/books/NBK1271/#vodi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="vodi.TF.1.2"><p class="no_margin">See Molecular Genetics for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="vodi.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="vodi.TF.1.4"><p class="no_margin">All pathogenic variants identified to date are in exons 2, 4, 5 and 8 with the most common being the c.642delC found in the Lebanese population [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>, <a class="bk_pop" href="#vodi.REF.ruga.2006">Ruga et al 2006</a>, <a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>, <a class="bk_pop" href="#vodi.REF.wang.2012.102">Wang et al 2012</a>].</p></div></dd><dt>5. </dt><dd><div id="vodi.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used can include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="vodi.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available</p></div></dd></dl></div></div></div></div></div><div id="vodi.Clinical_Characteristics"><h2 id="_vodi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="vodi.Clinical_Description"><h3>Clinical Description</h3><p>Hepatic veno-occlusive disease with immunodeficiency (VODI) is a primary immunodeficiency associated with terminal hepatic lobular vascular occlusion and hepatic lobule zone 3 fibrosis. All children in the cohort from Sydney, Australia presented prior to age six months, the majority with sequelae of the immunodeficiency either alone or concurrently with features of hepatic veno-occlusive disease (hVOD) (see <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_and_immunologic_features/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalandimmunologicfeatures" rid-ob="figobvodiTclinicalandimmunologicfeatures">Table 2</a>).</p><p><b>Immunodeficiency</b> is characterized by severe hypogammaglobulinemia, clinical evidence of T-cell immunodeficiency with normal numbers of circulating T and B cells, absent lymph node germinal centers, and absent tissue plasma cells [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>]. Bacterial and opportunistic infections including <i>Pneumocystis jirovecii</i> infection, mucocutaneous candidiasis, and enteroviral or cytomegalovirus infections occur.</p><p><b>Hepatic veno-occlusive disease (hVOD).</b> Ninety percent of the children with VODI present <i>ab initio</i> either with hepatomegaly (83% with preceding infection) or hepatic failure (53% with preceding infection). Typically, an infant has been unwell for several weeks, has become tachypneic, is failing to thrive, is admitted with interstitial pneumonitis caused by <i>Pneumocystis jirovecii</i>, is found to be jaundiced with ascites, has hypogammaglobulinemia and thrombocytopenia, and has evidence of hVOD.</p><p><b>Neurologic.</b> Overall, 30% of children with VODI had neurologic involvement; none of the individuals were reported to have veno-occlusive disease of the brain. Four individuals (sister of B II.1 and B II.2 [<a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>] and 3 unrelated children) had multiorgan failure associated with extensive cerebral necrosis on postmortem examination. A striking finding is the presence of cerebrospinal leukodystrophy in three individuals (20%) with VODI. Individual 5 had a leukodystrophy of unknown etiology and individual 6 developed this complication after a CMV-related gastroenteritis. In individual A II.1, the initial diagnosis of a cerebrovascular accident with a right-sided cerebral white matter lesion &#x02013; presumed to be <i>Toxoplasma</i> or a porencephalic cyst &#x02013; was revised as more consistent with cerebrospinal leukodystrophy. Individual B II.2 remained well on intravenous immunoglobulin (IVIG) and cotrimoxazole prophylaxis until age 18 years when she suddenly developed paraparesis and urinary retention associated with cerebral lesions. No infective cause or evidence of veno-occlusive disease was found on extensive investigation. There was partial response to high-dose IVIG and steroid therapy, suggesting an inflammatory etiology [MW Lin and M Wong, personal communication].</p><p><b>Other features.</b> Infants and children with VODI do not have <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features. Thrombocytopenia is frequent at presentation but may improve with resolution of the hVOD. One child had the syndrome of inappropriate ADH secretion, presumably as a manifestation of his cerebral leukodystrophy.</p><p><b>Morbidity/mortality.</b> VODI is associated with 100% mortality in the first year of life if unrecognized and untreated with IVIG or subcutaneous immunoglobulin (SCIG) replacement and <i>Pneumocystis jirovecii</i> prophylaxis, and a 90% mortality overall by the mid-teenage years [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>]. However, there have been only three deaths among eight recently ascertained <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals older than age one year, representing a markedly improved prognosis with early recognition and treatment [<a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>]. Should hVOD recovery occur, recurrence of hVOD appears to be prevented by continuation of IVIG and <i>Pneumocystis</i>
<i>jirovecii</i> prophylaxis. However, there may be an ongoing risk for neurologic inflammatory complications (B II.2). One child (Individual A II.1, <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>) died following recurrence of hVOD after bone marrow transplantation at age six years. <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_and_immunologic_features/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalandimmunologicfeatures" rid-ob="figobvodiTclinicalandimmunologicfeatures">Table 2</a> summarizes the clinical and immunologic features of the 20 individuals from Sydney with the clinical diagnosis of VODI (including the 11 individuals who were able to be investigated by molecular analysis confirming the presence of <i>SP110</i> pathogenic variants) and eight newly ascertained individuals [<a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>].</p><div id="vodi.T.clinical_and_immunologic_features" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Clinical and Immunologic Features of Hepatic Veno-Occlusive Disease with Immunodeficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.T.clinical_and_immunologic_features/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.T.clinical_and_immunologic_features_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Features</th><th id="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals from Sydney w/VODI&#x000a0;<sup>1</sup></th><th id="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comments</th><th id="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Newly Ascertained Individuals w/VODI w/Novel Pathogenic Variants&#x000a0;<sup>2</sup></th></tr></thead><tbody><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Presenting &#x0003c;6 months</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20/20 (100%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/8</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic failure at initial presentation</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/20 (20%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/12 post-HSCT<br />3/12 no obvious precipitant</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0/8</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatomegaly at initial presentation</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9/20 (45%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/6 <i>P. jirovecii</i><br />2/6 hepatomegaly w/out SOS</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6/8<br />1/8 enterovirus &#x00026; disseminated cytomegalovirus <sup>3</sup></td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>P. jirovecii</i> infection</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12/20 (60%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7/12 proven<br />5/12 suspected</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/8 suspected&#x000a0;<sup>3</sup><br />1/8 proven&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mucocutaneous candidiasis</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/20 (10%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/8</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other features</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/20 (5%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">By age 19 years</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/8 lung fibrosis&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Death</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19/20 (95%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/8 (38%)</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recovery from initial SOS</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/20 (20%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 completely well<br />1 chronic liver disease requiring hepatic transplantation<br />1 SOS post-HSCT<br />1 developmental disability, chronic aspiration</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/8</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic abnormalities</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6/20 (35%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/7 cerebral infarction<br />2/7 leukodystrophy</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/8 leukodystrophy</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Panhypogammaglobulinemia</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19/19 (100%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/18 loss of normal immunoglobulins at age 4 mos</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/5 tested<br />1/5 low normal levels of IgA &#x00026; IgM after commencing IVIG</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal number of lymphocytes</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10/11 (92%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8/8</td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal NK cells</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12/12 (100%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/3&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Decreased intracytoplasmic IFN-&#x003b3;, IL-2, IL-4, IL-10</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/5 (80%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low levels at 4 hrs, normal/increased levels at 48 hrs</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/1&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Decreased number of memory T &#x00026; B cells</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3/4 (75%)</td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_vodi.T.clinical_and_immunologic_features_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2/3&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">HSCT = hematopoietic stem cell transplantation</p></div></dd><dt></dt><dd><div><p class="no_margin">IVIG = intravenous immunoglobulin</p></div></dd><dt></dt><dd><div><p class="no_margin">SOS = sinusoidal obstruction syndrome</p></div></dd><dt>1. </dt><dd><div id="vodi.TF.2.1"><p class="no_margin">Table modified from <a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al [2006]</a></p></div></dd><dt>2. </dt><dd><div id="vodi.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a></p></div></dd><dt>3. </dt><dd><div id="vodi.TF.2.3"><p class="no_margin">See <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>, Affected individual 1</p></div></dd><dt>4. </dt><dd><div id="vodi.TF.2.4"><p class="no_margin">See <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>, Affected individual 4</p></div></dd><dt>5. </dt><dd><div id="vodi.TF.2.5"><p class="no_margin">See <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>, Affected individual 2</p></div></dd><dt>6. </dt><dd><div id="vodi.TF.2.6"><p class="no_margin">Memory T and B cells were present in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual 1 (see <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>)</p></div></dd></dl></div></div></div><p><a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a> outlines clinical features in individuals with identified <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>SP110</i> pathogenic variants [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>, <a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>, <a class="bk_pop" href="#vodi.REF.wang.2012.102">Wang et al 2012</a>, <a class="bk_pop" href="#vodi.REF.ganaiem.2013.250">Ganaiem et al 2013</a>].</p><div id="vodi.T.clinical_features_of_individuals" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Clinical Features of Individuals Homozygous for <i>SP110</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.T.clinical_features_of_individuals_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Affected Individual</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SP110</i> (LRG_109) Pathogenic Variant</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Presentation</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum Igs</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Memory T/B Cells</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">T Cell Cytokines</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Findings</th><th id="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deceased</th></tr></thead><tbody><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A II.1&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 5 mos: immunodeficiency, thrombocytopenia, SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Left hemiparesis&#x000a0;<sup>2</sup>, recurrent hVOD w/GVHD post-HSCT</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">B II.1&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Age 7 mos: immunodeficiency</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic lung disease secondary to recurrent aspiration</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes (age 19 yrs)</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">B II.2&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Age 6 mos: hepatosplenomegaly, ascites, SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Well until 18 yrs (developed paraparesis, urinary retention, cerebral lesions)</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">C II.1&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Age 4 mos: hepatosplenomegaly, ascites, SOS, thrombocytopenia, mucocutaneous candidiasis</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic liver disease, portal hypertension post-hepatic transplantation</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">D II.1&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: hepatosplenomegaly, ascites, SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;&#x000a0;<sup>3</sup></td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hemophagocytic syndrome post-hepatic transplantation</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: hepatosplenomegaly, ascites, SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pulmonary hemorrhage, multiorgan failure</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos, respiratory distress</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SIADH, <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> cerebrospinal leukodystrophy</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: chronic cough, diarrhea<br />Age 8 yrs: hepatosplenomegaly<br />Age &#x02265;12 yrs: hVOD</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Idiopathic left frontal lobe calcified cyst, epilepsy, CMV colitis, post-diarrheal encephalomyelitis w/lower limb paralysis, cerebrospinal leukodystrophy, esophageal candidiasis, duodenal lymphocytic infiltrate</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC presumed&#x000a0;<sup>5</sup></td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 2 mos: chronic diarrhea, failure to thrive, middle ear and respiratory infections, hepatosplenomegaly, thrombocytopenia</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly, hepatic biopsy consistent w/SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes, 11 mos from diarrhea leading to septic shock</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC presumed&#x000a0;<sup>5</sup></td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 5 mos: upper respiratory illness<br />Age 8 mos: chronic diarrhea, hepatomegaly, thrombocytopenia</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic biopsy consistent w/SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes, 3.5 yrs from diarrhea leading to septic shock</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9&#x000a0;<sup>4</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC presumed&#x000a0;<sup>5</sup></td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 2 mos: ascites, hepatomegaly, anemia, thrombocytopenia</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic biopsy consistent w/SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes, 2.5 mos from otitis, diarrhea, pneumonia</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">E I.1&#x000a0;<sup>1</sup><br />Lebanese</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.40delC in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: immunodeficiency, thrombocytopenia, hepatosplenomegaly w/out definite evidence of SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Enteroviral and <i>P. jirovecii</i> infection</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Yes</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4&#x000a0;<sup>4</sup><br />Hispanic</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.78_79delinsAT (p.Ile27Leu) in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 5 mos: hepatosplenomegaly, fever, respiratory distress, pancytopenia</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stable &#x00026; well</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1&#x000a0;<sup>4</sup><br />Italian</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.319_325dup GGTGCTT in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 11 mos: hepatosplenomegaly, disseminated CMV, rotavirus gastroenteritis, vulvar abscesses, SOS</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193; initially</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recovering from hVOD, well</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2&#x000a0;<sup>4</sup><br />Italian</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.667+1dup <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5 <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a></td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: hepatosplenomegaly, failure to thrive, respiratory distress/lung fibrosis, diarrhea</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02193;</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hepatic biopsy consistent w/sinusoidal dilatation, moderate central vein &#x00026; perivenular subsinusoidal fibrosis; stable w/improvement</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr><tr><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3&#x000a0;<sup>4</sup><br />Palestinian Arab</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.373del in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 3 mos: diagnosis of VODI confirmed w/cascade testing prior to illness onset. No hepatomegaly or liver function abnormalities</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Stable &#x00026; well</td><td headers="hd_h_vodi.T.clinical_features_of_individuals_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Modified from <a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al [2006]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">CMV = cytomegalovirus</p></div></dd><dt></dt><dd><div><p class="no_margin">GVHD = graft-versus-host disease</p></div></dd><dt></dt><dd><div><p class="no_margin">HSCT = hematopoietic stem cell transplantation</p></div></dd><dt></dt><dd><div><p class="no_margin">hVOD = hepatic veno-occlusive disease</p></div></dd><dt></dt><dd><div><p class="no_margin">SOS = sinusoidal obstruction syndrome</p></div></dd><dt></dt><dd><div><p class="no_margin">SIADH = syndrome of inappropriate antidiuretic hormone secretion</p></div></dd><dt></dt><dd><div><p class="no_margin">Note: Although families A, B, and C are not known to be related, they are believed to have a common ancestor. Individuals included in the initial homozygosity mapping analysis: A II.1, B II.1, B II.2, C II.1, 16 (&#x02018;G&#x02019; in initial analysis), and 5 (&#x02018;J&#x02019; in initial analysis).</p></div></dd><dt></dt><dd><div><p class="no_margin">Affected individual designations are those used in the articles cited.</p></div></dd><dt>1. </dt><dd><div id="vodi.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al [2006]</a></p></div></dd><dt>2. </dt><dd><div id="vodi.TF.3.2"><p class="no_margin">Secondary to cerebral white matter abnormality</p></div></dd><dt>3. </dt><dd><div id="vodi.TF.3.3"><p class="no_margin">IgA and IgM serum concentrations increased to lower limit of normal while on IVIG.</p></div></dd><dt>4. </dt><dd><div id="vodi.TF.3.4"><p class="no_margin"><a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a></p></div></dd><dt>5. </dt><dd><div id="vodi.TF.3.5"><p class="no_margin">The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> listed is a known <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> variant. While <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> was not performed on this <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, c.642delC is presumed to be the pathogenic variant based on the family history.</p></div></dd></dl></div></div></div></div><div id="vodi.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No significant difference in the clinical manifestations of VODI is observed between individuals with different pathogenic variants.</p><p>The one child with an out-of-frame <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 (Individual 1, <a class="figpopup" href="/books/NBK1271/table/vodi.T.clinical_features_of_individuals/?report=objectonly" target="object" rid-figpopup="figvodiTclinicalfeaturesofindividuals" rid-ob="figobvodiTclinicalfeaturesofindividuals">Table 3</a>) presented at age 11 months (later than average) with disseminated CMV infection, which has not been noted in other children with VODI. In addition, the numbers of memory T and B cells were normal and intracellular cytokine production was normal &#x02013; findings not observed in other children with VODI.</p></div><div id="vodi.Penetrance"><h3>Penetrance</h3><p>Penetrance for the combined B- and T-cell immunodeficiency has been 100% in individuals confirmed to have VODI caused by pathogenic variants in <i>SP110</i>. Likewise, hVOD has been described in all probands or their <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs.</p><p>Approximately 10% of children with VODI, ascertained at a young age because of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sib and treated early in the disease course with IVIG, may manifest immunodeficiency only at presentation.</p></div><div id="vodi.Nomenclature"><h3>Nomenclature</h3><p>Hepatic veno-occlusive disease alone was known previously as Jamaican bush tea disease due to a dietary and geographic association. This term is now superseded by hepatic veno-occlusive disease (hVOD) or sinusoidal obstruction syndrome (SOS), terms less limiting given the occurrence of hVOD worldwide and it being secondary to other precipitants. The combination of hVOD and a combined immunodeficiency is termed VODI.</p></div><div id="vodi.Prevalence"><h3>Prevalence</h3><p>VODI was described originally in Australians of Lebanese origin by <a class="bk_pop" href="#vodi.REF.mellis.1976.236">Mellis &#x00026; Bale [1976]</a>. Subsequently, the majority of children reported with VODI have been of Lebanese origin. The prevalence of VODI in the Lebanese population of Sydney, Australia has been calculated at one in 2,500 [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>]. Unpublished data from Australia and Lebanon suggest that VODI associated with the <i>SP110</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 5 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.642delC is found not infrequently in families of Lebanese background, especially in association with <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>. This in turn suggests that the diagnosis has been missed in expatriate Lebanese communities.</p><p>The prevalence of VODI in children of non-Lebanese origin is unknown; however, the following reports suggest that the VODI <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is observed in other populations. Additional reports of VODI:</p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case of VODI (i.e., a single occurrence in a family) with humoral and cellular immunodeficiency in the Spanish literature</div></li><li class="half_rhythm"><div>Two Italian children with VODI [<a class="bk_pop" href="#vodi.REF.ruga.2006">Ruga et al 2006</a>, <a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>]</div></li><li class="half_rhythm"><div>A Hispanic child with VODI from the United States [<a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>, <a class="bk_pop" href="#vodi.REF.wang.2012.102">Wang et al 2012</a>]</div></li></ul></div></div><div id="vodi.Genetically_Related_Allelic_Disorde"><h2 id="_vodi_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No allelic Mendelian disorders for <i>SP110</i> or contiguous-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> disorders including the <i>SP110</i> region associated with hVOD or immunodeficiency have been described.</p></div><div id="vodi.Differential_Diagnosis"><h2 id="_vodi_Differential_Diagnosis_">Differential Diagnosis</h2><p>Although sinusoidal obstruction syndrome in association with severe combined immunodeficiency (SCID) was described in an individual reported by <a class="bk_pop" href="#vodi.REF.washington.1993.485">Washington et al [1993]</a>, and in one postmortem HIV cohort reported by <a class="bk_pop" href="#vodi.REF.buckley.1995.398">Buckley &#x00026; Hutchins [1995]</a>, the lack of a recognized and replicated association of immunodeficiency with hepatic veno-occlusive disease (hVOD) in other classes of immunodeficiency suggests that hVOD may be a primary feature of VODI rather than secondary to an immunodeficiency per se.</p><p>The primary differential diagnosis for hVOD alone would be environmental alkaloid or sinusoidal cell toxicity. However, hVOD has also been reported in association with alcoholic cirrhosis [<a class="bk_pop" href="#vodi.REF.kishi.1999.47s">Kishi et al 1999</a>], <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> [<a class="bk_pop" href="#vodi.REF.srisirirojanakorn.1999.786">Srisirirojanakorn et al 1999</a>], osteopetrosis [<a class="bk_pop" href="#vodi.REF.corbacioglu.2006.547">Corbacioglu et al 2006</a>] (see <a href="/books/n/gene/clcn7/"><i>CLCN7</i>-Related Osteopetrosis</a>), and hypereosinophilic syndrome (OMIM <a href="http://omim.org/entry/607685" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607685</a>). HIV should also be considered in the differential diagnosis for the immune <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Previous case-control studies using single-nucleotide polymorphisms (SNPs) have also reported associations between hVOD and SNPs in the carbamoyl phosphate synthetase 1 <i>(CPS1</i>) (see <a href="/books/n/gene/ucd-overview/">Urea Cycle Disorders Overview</a>), <a href="/books/n/gene/factor-v-leiden/">factor V Leiden</a> (FVL), <i>HFE</i> (see <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-Associated Hereditary Hemochromatosis</a>), and glutathione S-transferase <i>(GSTM1</i> and <i>GSTT1</i>) genes. Relative risks of 8.6 for the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>HFE</i> Cys282Tyr <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> and 4.12 for the <i>GSTM1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> allele have been reported [<a class="bk_pop" href="#vodi.REF.srivastava.2004.1574">Srivastava et al 2004</a>, <a class="bk_pop" href="#vodi.REF.kallianpur.2005.1">Kallianpur 2005</a>, <a class="bk_pop" href="#vodi.REF.kallianpur.2005.1155">Kallianpur et al 2005</a>]. No independent replication of these findings has been performed.</p><p>There has been no report of <i>SP110</i> pathogenic variants in individuals described to have hVOD without immunodeficiency.</p></div><div id="vodi.Management"><h2 id="_vodi_Management_">Management</h2><div id="vodi.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hepatic veno-occlusive disease with immunodeficiency (VODI), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Assessment of immune function including serum immunoglobulin levels, T- and B-cell numbers and percentages, and T-cell proliferative response to mitogens</div></li><li class="half_rhythm"><div>More extensive immune testing for number of memory B and T cells and intracellular cytokine (IL2, IL4, IL6, and IFN&#x003b3;) responses to stimulation, if available</div></li><li class="half_rhythm"><div>Complete blood count</div></li><li class="half_rhythm"><div>Assessment of hepatic function (including serum concentrations of aminotransferases, bilirubin, and albumin) and assessment for sequelae of portal hypertension (including anemia and thrombocytopenia)</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>A clotting profile and a hepatic Doppler ultrasound examination should be undertaken prior to consideration of hepatic biopsy for a histologic diagnosis of hepatic veno-occlusive disease (hVOD). Evidence of impaired clotting and/or portal hypertension contraindicates hepatic biopsy.</p></div><div id="vodi.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Hypogammaglobulinemia</b> is treated via intravenous immunoglobulin (IVIG), which should commence at the diagnosis of VODI or in presymptomatic sibs confirmed to have <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>SP110</i> pathogenic variants. An appropriate dose is 0.4 g/kg every four weeks adjusting the dose to maintain a trough IgG level greater than 6 g/L.</p><p><b><i>Pneumocystis jirovecii</i> prophylaxis</b> with cotrimoxazole pediatric suspension (5 mL = trimethoprim 40 mg and sulfamethoxazole 200 mg) should be ongoing in children with VODI who tolerate this medication. This may be administered as a single daily dose or as a single dose three days per week. The recommended dose is 5 mg trimethoprim per kg (0.625 mL/kg) or 150 mg/M<sup>2</sup> (3.75 mL/M<sup>2</sup>).</p><p><b>Infections with specific agents</b> should be treated with appropriate supportive care and antibacterials or antivirals.</p><p><b>Hepatic transplantation</b> may be considered, but appears to have a high rate of complications in the VODI cohort studied to date (see <a href="#vodi.Other">Other</a>).</p><p><b>Bone marrow transplantation.</b>
<a class="bk_pop" href="#vodi.REF.ganaiem.2013.250">Ganaiem et al [2013]</a> reported that this may be an efficacious treatment modality with appropriate conditioning therapy (see <a href="#vodi.Other">Other</a>).</p></div><div id="vodi.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Initiation of regular IVIG at the time of diagnosis to prevent infection related to severe hypogammaglobulinemia and cotrimoxazole prophylaxis to prevent <i>Pneumocystis jirovecii</i> infection is appropriate (see <a href="#vodi.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="vodi.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Some evidence suggests that treatment of immunodeficiency early in VODI may reduce the risk for development or recurrence of hVOD.</p></div><div id="vodi.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Regular surveillance of hepatic function, platelet count, and hemoglobin level in children with VODI as hepatic failure and portal hypertension may occur</div></li><li class="half_rhythm"><div>Surveillance of serum and urine electrolytes as the syndrome of inappropriate anti-diuretic hormone (SIADH) may occur</div></li><li class="half_rhythm"><div>Measurement of immunoglobulin concentrations prior to IVIG infusions</div></li><li class="half_rhythm"><div>Broncho-alveolar lavage to diagnose <i>Pneumocystis jirovecii</i> infection; viral cultures or lung function studies as needed</div></li><li class="half_rhythm"><div>Cerebrospinal imaging to diagnose leukodystrophy when clinically indicated</div></li></ul></div><div id="vodi.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Agents known to predispose to hVOD (e.g., cyclophosphamide and senecio alkaloids/bush teas) should be avoided.</p></div><div id="vodi.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who are younger than age 12 months in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures. The majority of children with VODI present before age six months; however, as one child presented at age 11 months, testing should be considered in sibs of a proband who are younger than age 12 months.</p><p>Evaluations include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known;</div></li><li class="half_rhythm"><div>Serum immunoglobulins, full blood count and liver function tests at birth and repeated at six months if the pathogenic variants in the family are not known.</div></li></ul><p>Penetrance is complete (i.e., 100%) in the individuals with VODI described to date; thus, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of healthy at-risk sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who are older than age 12 months is not recommended.</p><p>See <a href="#vodi.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="vodi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>For an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnant woman, ongoing intravenous immunoglobulin to prevent infection related to severe hypogammaglobulinemia and cotrimoxazole prophylaxis to prevent <i>Pneumocystis jirovecii</i> infection is appropriate during pregnancy. There is evidence that early treatment of a baby known to be <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for pathogenic <i>SP110</i> pathogenic variants may result in improved long-term outcomes.</p></div><div id="vodi.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="vodi.Other"><h3>Other</h3><p>Hepatic VOD (hVOD) has been reported in the Australian cohort with VODI following hematopoietic stem cell transplantation (HSCT); therefore, individuals with VODI are likely to have at least the population risk for hVOD following HSCT. The first successful HSCT was reported by <a class="bk_pop" href="#vodi.REF.ganaiem.2013.250">Ganaiem et al [2013]</a> suggesting that this may be an efficacious treatment modality with appropriate conditioning therapy. Ganaiem et al described a <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> Arab family with eight <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; five individuals received HSCT, of which three were successful. All five individuals received matched sib or family member bone marrow (4 individuals) or peripheral stem cells (1 individual). All five individuals received conditioning with fludarabine and serotherapy and an alkylating agent (cyclophosphamide, busulfan, or treosulfan). The two individuals who died also received thiotepa, and following engraftment died with hVOD and multiorgan failure. One child has remained well for two years following uncomplicated HSCT in 2014. She was of consanguineous Lebanese background and presented at age four months with probable herpetic hepatitis which initially responded clinically to acyclovir, but then developed florid hVOD following a transfusion. She responded well to IVIG, prophylactic Bactrim&#x02122;, and defibrotide. She was neurologically normal, but asymptomatic bilateral subdural hematomas were found on routine pre-transplant MRI despite a normal head ultrasound a week prior when coagulation studies and platelets had already normalized. At age six months she underwent an unrelated cord blood transplant with alemtuzumab, fludarabine, treosulfan and antithymocyte globulin conditioning. Defibrotide was prophylactically continued until two months post transplant. She remains neurologically normal and her MRI scan at age two years showed no anatomic abnormality [M Wong, personal communication].</p><p>In 2016, an Australian infant of <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> Lebanese background presented at age four months with <i>Pneumocystis</i>, CMV infection, and hVOD with hypogammaglobinemia. A <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>SP110</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (c.642delC) was identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. At age five months, after control of pneumonitis and hVOD, he received a haplo-identical paternal HSCT after depletion of &#x003b1;/&#x003b2; TCR and CD19+ cells. He received conditioning with fludarabine, treosulfan, and antithymocyte globulin. Defibrotide was given as hVOD prophylaxis. Two months post transplant he was well and had engrafted without GVHD or recurrence of hVOD but with moderate CMV hepatitis. Defibrotide was able to be discontinued at day 60. Both the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and donor were CMV positive prior to transplant. Seventy days following HSCT he developed seizures. MRI showed extensive abnormalities throughout the brain and spinal cord, including areas of edema and ring-like enhancing lesions. CT showed widespread calcifications. CMV retinitis was apparent and both CSF and vitreous were CMV <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> positive [T Cole, J Smart, and T Soosay Raj, personal communication].</p><p>Inclusion of defibrotide prophylaxis in the transplant regimen may improve survival. Omission of a second alkylating agent in the conditioning regimen may reduce the risk for transplant-related hVOD.</p></div></div><div id="vodi.Genetic_Counseling"><h2 id="_vodi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="vodi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hepatic veno-occlusive disease with immunodeficiency (VODI) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Penetrance is complete.</p></div><div id="vodi.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>SP110</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>An at-risk sib older than age 12 months and known to be unaffected has a 2/3 risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with hepatic veno-occlusive disease with immunodeficiency are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SP110</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SP110</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="vodi.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SP110</i> pathogenic variants in the family.</p></div><div id="vodi.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#vodi.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives younger than age 12 months for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="vodi.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SP110</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for VODI are possible.</p></div></div><div id="vodi.Resources"><h2 id="_vodi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>International Patient Organisation for Primary Immunodeficiencies (IPOPI)</b></div><div>Firside</div><div>Main Road</div><div>Downderry Cornwall PL11 3LE</div><div>United Kingdom</div><div><b>Phone:</b> +44 01503 250 668</div><div><b>Fax:</b> +44 01503 250 668</div><div><b>Email:</b> info@ipopi.org</div><div><a href="http://ipopi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ipopi.org</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li></ul></div><div id="vodi.Molecular_Genetics"><h2 id="_vodi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="vodi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hepatic Veno-Occlusive Disease with Immunodeficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_vodi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_vodi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_vodi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_vodi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_vodi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_vodi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_vodi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/3431" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SP110</i></a></td><td headers="hd_b_vodi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=3431" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q37<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_vodi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9HB58" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sp110 nuclear body protein</a></td><td headers="hd_b_vodi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SP110" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SP110 database</a><br /><a href="http://structure.bmc.lu.se/idbase/SP110base/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SP110base</a></td><td headers="hd_b_vodi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SP110" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SP110</a></td><td headers="hd_b_vodi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SP110[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SP110</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="vodi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="vodi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hepatic Veno-Occlusive Disease with Immunodeficiency (<a href="/omim/235550,604457" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/235550" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">235550</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604457" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604457</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NUCLEAR BODY PROTEIN SP110; SP110</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>SP110</i> encodes three major <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>:</p><ul><li class="half_rhythm"><div>Sp110 isoform A, <a href="/nuccore/NM_004509.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004509.3</a> (average mass 78.438 kd; transcript does not include <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 17)</div></li><li class="half_rhythm"><div>Isoform B, <a href="/nuccore/NM_004510.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004510.3</a> (average mass 61.940 kd; transcript includes an alternate <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15 and terminates within exon 15)</div></li><li class="half_rhythm"><div>Isoform C, <a href="/nuccore/NM_080424.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_080424.2</a> (average mass 81.211 kd; full-length transcript including <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 17 and terminating at exon 19)</div></li></ul><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK1271/table/vodi.T.sp110_pathogenic_variants_discuss/?report=objectonly" target="object" rid-figpopup="figvodiTsp110pathogenicvariantsdiscuss" rid-ob="figobvodiTsp110pathogenicvariantsdiscuss">Table 4</a>. The majority of these pathogenic variants cause a frameshift with consequent protein truncation. The c.642delC <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in multiple probands of Lebanese ancestry [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>, <a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>].</p><div id="vodi.T.sp110_pathogenic_variants_discuss" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>SP110</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1271/table/vodi.T.sp110_pathogenic_variants_discuss/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__vodi.T.sp110_pathogenic_variants_discuss_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Exon</th><th id="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference</th><th id="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.40delC</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln14SerfsTer25</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al [2006]</a></td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_5" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_080424.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_080424<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_536349.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_536349<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.78_79delinsAT<br />(78_79CA&#x0003e;AT)</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile27Leu</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a>, <a class="bk_pop" href="#vodi.REF.wang.2012.102">Wang et al [2012]</a></td></tr><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.319_325dupGGTGCTT</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser109TrpfsTer5</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.ruga.2006">Ruga et al [2006]</a>, <a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a></td></tr><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.373delA</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr125LeufsTer3</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a>, <a class="bk_pop" href="#vodi.REF.ganaiem.2013.250">Ganaiem et al [2013]</a></td></tr><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.642delC</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro214ProfsTer14</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al [2006]</a></td></tr><tr><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.667+1dupG</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_vodi.T.sp110_pathogenic_variants_discuss_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al [2012]</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd><dt>1. </dt><dd><div id="vodi.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Sp110 is expressed primarily in leukocytes and spleen; it is induced by interferon gamma and all-trans retinoic acid (ATRA). SP110 isoform B has been described as showing activity as a potent transcriptional co-repressor of retinoic acid receptor alpha (RAR&#x003b1;) perhaps via competitive exclusion of activators at receptor [<a class="bk_pop" href="#vodi.REF.watashi.2003.7498">Watashi et al 2003</a>].</p><p>The Sp110 nuclear body protein is a member of the Sp100/Sp140 promyelocytic leukemia nuclear body (PML NB) protein family. The protein has an Sp100 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (amino acids 6-159), which is involved in dimerization with other Sp100 family proteins, a nuclear localization signal (amino acids 288-306) and a nuclear hormone interaction domain (LXXLL type), which may act as an ATRA response element. Other domains that are common features of modular proteins involved in chromatin-mediated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> transcription include a SAND domain (amino acids 452-532), a plant homeobox domain (amino acids 537-577), and a bromodomain (amino acids 606-674) [<a class="bk_pop" href="#vodi.REF.bloch.2000.6138">Bloch et al 2000</a>].</p><p>The Sp110 nuclear body protein is associated with the PML NB, a nuclear macromolecular complex, which is deployed to areas of active host or viral DNA replication, transcription, and repair and has been reported to be involved in apoptosis, cell cycle control, and the immune response.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> EBV-transformed B cells from an individual with VODI and a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> <i>SP110</i> variant have shown an absence of nuclear Sp100-specific immunolabeling in a setting of normal numbers of PML nuclear bodies. This finding is consistent with Sp110 protein having an important role in the immune response without being essential for PML nuclear body formation [<a class="bk_pop" href="#vodi.REF.roscioli.2006.620">Roscioli et al 2006</a>].</p><p>Most pathogenic variants associated with VODI are <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants. The c.78_79delinsAT (p.Ile27Leu) <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> occurs at the highly conserved p.Ile27 within the highly conserved Sp100 <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (see <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>). The c.78_79delinsAT (p.Ile27Leu) pathogenic variant greatly reduces Sp110 stability [<a class="bk_pop" href="#vodi.REF.cliffe.2012.735">Cliffe et al 2012</a>].</p><p><b>Pathophysiology.</b> It is currently unknown whether the hVOD is a direct manifestation of <i>SP110</i> sequence variants, related to altered apoptosis in the hepatic sinusoid, or secondary to infection; however, hVOD appears to develop after infections occur.</p></div><div id="vodi.References"><h2 id="_vodi_References_">References</h2><div id="vodi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.bloch.2000.6138">Bloch DB, Nakajima A, Gulick T, Chiche JD, Orth D, de La Monte SM, Bloch KD. Sp110 localizes to the PML-Sp100 nuclear body and may function as a nuclear hormone receptor transcriptional coactivator. <span><span class="ref-journal">Mol Cell Biol. </span>2000;<span class="ref-vol">20</span>:6138–46.</span> [<a href="/pmc/articles/PMC86089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC86089</span></a>] [<a href="/pubmed/10913195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10913195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.buckley.1995.398">Buckley JA, Hutchins GM. Association of hepatic veno-occlusive disease with the acquired immunodeficiency syndrome. <span><span class="ref-journal">Mod Pathol. </span>1995;<span class="ref-vol">8</span>:398–401.</span> [<a href="/pubmed/7567938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7567938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.cliffe.2012.735">Cliffe ST, Bloch DB, Suryani S, Kamsteeg EJ, Avery DT, Palendira U, Church JA, Wainstein BK, Trizzino A, Lefranc G, Akatcherian C, Megarban&#x000e9; A, Gilissen C, Moshous D, Reichenbach J, Misbah S, Salzer U, Abinun M, Ong PY, Stepensky P, Ruga E, Ziegler JB, Wong M, Tangye SG, Lindeman R, Buckley MF, Roscioli T. Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2012;<span class="ref-vol">130</span>:735–742.e6.</span> [<a href="/pubmed/22621957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22621957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.corbacioglu.2006.547">Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W, Schulz AS. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. <span><span class="ref-journal">Bone Marrow Transplant. </span>2006;<span class="ref-vol">38</span>:547–53.</span> [<a href="/pubmed/16953210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16953210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.ganaiem.2013.250">Ganaiem H, Eisenstein EM, Tenenbaum A, Somech R, Simanovsky N, Roscioli T, Weintraub M, Stepensky P. The role of hematopoietic stem cell transplantation in SP110 associated veno-occlusive disease with immunodeficiency syndrome. <span><span class="ref-journal">Pediatr Allergy Immunol. </span>2013;<span class="ref-vol">24</span>:250–6.</span> [<a href="/pubmed/23448538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23448538</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.kallianpur.2005.1">Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: has the time come? <span><span class="ref-journal">Bone Marrow Transplant. </span>2005;<span class="ref-vol">35</span>:1–16.</span> [<a href="/pubmed/15489868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15489868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.kallianpur.2005.1155">Kallianpur AR, Hall LD, Yadav M, Byrne DW, Speroff T, Dittus RS, Haines JL, Christman BW, Summar ML. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. <span><span class="ref-journal">Bone Marrow Transplant. </span>2005;<span class="ref-vol">35</span>:1155–64.</span> [<a href="/pubmed/15834437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15834437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.kishi.1999.47s">Kishi M, Maeyama S, Ogata S, Koike J, Uchikoshi T. Hepatic veno-occlusive lesions in severe alcoholic hepatitis and alcoholic liver cirrhosis: a comparative histopathological study in autopsy cases. <span><span class="ref-journal">Alcohol Clin Exp Res. </span>1999;<span class="ref-vol">23</span>:47S–51S.</span> [<a href="/pubmed/10235278" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10235278</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.mellis.1976.236">Mellis C, Bale PM. Familial hepatic venoocclusive disease with probable immune deficiency. <span><span class="ref-journal">J Pediatr. </span>1976;<span class="ref-vol">88</span>:236–42.</span> [<a href="/pubmed/1249685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1249685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.roscioli.2006.620">Roscioli T, Cliffe ST, Bloch DB, Bell CG, Mullan G, Taylor PJ, Sarris M, Wang J, Donald JA, Kirk EP, Ziegler JB, Salzer U, McDonald GB, Wong M, Lindeman R, Buckley MF. Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:620–2.</span> [<a href="/pubmed/16648851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16648851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.ruga.2006">Ruga EM, Guariso G, Antiga LD, Guido M, Fassan M, Elia RD, Ziegler JB, Roscioli T, Cliffe ST, Buckley MF, Zancan L. Hepatic veno-occlusive disease with immunodeficiency syndrome: case report. Budapest, Hungary: 12th Meeting of the European Society for Immunodeficiencies. 2006.</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.srisirirojanakorn.1999.786">Srisirirojanakorn N, Finegold MJ, Gopalakrishna GS, Klish WJ. Hepatic veno-occlusive disease in ataxia-telangiectasia. <span><span class="ref-journal">J Pediatr. </span>1999;<span class="ref-vol">134</span>:786–8.</span> [<a href="/pubmed/10356154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10356154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.srivastava.2004.1574">Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. <span><span class="ref-journal">Blood. </span>2004;<span class="ref-vol">104</span>:1574–7.</span> [<a href="/pubmed/15142875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15142875</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.wang.2012.102">Wang T, Ong P, Roscioli T, Cliffe ST, Church JA. Hepatic veno-occlusive disease with immunodeficiency (VODI): first reported case in the U.S. and identification of a unique mutation in Sp110. <span><span class="ref-journal">Clin Immunol. </span>2012;<span class="ref-vol">145</span>:102–7.</span> [<a href="/pubmed/22982295" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22982295</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.washington.1993.485">Washington K, Gossage DL, Gottfried MR. Pathology of the liver in severe combined immunodeficiency and DiGeorge syndrome. <span><span class="ref-journal">Pediatr Pathol. </span>1993;<span class="ref-vol">13</span>:485–504.</span> [<a href="/pubmed/8372033" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8372033</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="vodi.REF.watashi.2003.7498">Watashi K, Hijikata M, Tagawa A, Doi T, Marusawa H, Shimotohno K. Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus. <span><span class="ref-journal">Mol Cell Biol. </span>2003;<span class="ref-vol">23</span>:7498–509.</span> [<a href="/pmc/articles/PMC207568/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC207568</span></a>] [<a href="/pubmed/14559998" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14559998</span></a>]</div></li></ul></div></div><div id="vodi.Chapter_Notes"><h2 id="_vodi_Chapter_Notes_">Chapter Notes</h2><div id="vodi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 January 2017 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 July 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 September 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 February 2007 (me) Review posted live</div></li><li class="half_rhythm"><div>29 November 2006 (mb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1271</span><span class="label">PMID: <a href="/pubmed/20301448" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301448</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hemo-b/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hep/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1271&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1271/?report=reader">PubReader</a></li><li><a href="/books/NBK1271/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1271" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1271" style="display:none" title="Cite this Page"><div class="bk_tt">Roscioli T, Ziegler JB, Buckley M, et al. Hepatic Veno-Occlusive Disease with Immunodeficiency. 2007 Feb 21 [Updated 2017 Jan 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1271/pdf/Bookshelf_NBK1271.pdf">PDF version of this page</a> (551K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#vodi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#vodi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#vodi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#vodi.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#vodi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#vodi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#vodi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#vodi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#vodi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#vodi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#vodi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=3431[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SP110</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1271+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1487960" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1487960" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1487960" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1487960" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301584" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allenspach E, Rawlings DJ, Scharenberg AM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301656" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hershfield M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301501" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sweeney WE, Avner ED. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301489" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glycogen Storage Disease Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bali DS, Chen YT, Austin S, Goldstein JL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301777" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ZAP70</i>-Related Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ZAP70</i>-Related Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Walkovich K, Vander Lugt M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301448" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301448" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0416d475f66d18aa656283">Hepatic Veno-Occlusive Disease with Immunodeficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hepatic Veno-Occlusive Disease with Immunodeficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:11:32-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B994AE041150100000000026E0101&amp;ncbi_session=CE8B994AE0416D31_0622SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1271%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1271&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1271/&amp;ncbi_pagename=Hepatic Veno-Occlusive Disease with Immunodeficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B994AE0416D31_0622SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>